

NOV 6 2004

PAGE 369 • RCV'D AT 11/09/2004 12:21:07 PM • FAX SYSTEM Standard Time • SVR-USPTO-FAXE:1/4 • DUNS:8729306 • CSID:1 612 305 1228 • DURATION (MM:SS):00:08

Amendment and Response

Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIA

Page 2 of 15

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

Listing of Claims

1. (Currently amended) A method of determining whether an individual has or is at risk for developing Usher syndrome Type IIa, the method comprising:
 1. obtaining a biological sample from the individual, wherein the biological sample is from a tissue that normally includes the usherin protein in an individual not having Usher syndrome Type IIa;
 2. incubating the biological sample with at least one antibody which is immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 under conditions effective to produce an immunoconjugate if the usherin protein is present, wherein the at least one antibody which is immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 does not cross-react with other non-usherin proteins within the biological sample;
 3. evaluating for the presence or absence of the immunoconjugate; and
 4. correlating the presence of the immunoconjugate with the individual not having Usher syndrome Type IIa, and the absence of the immunoconjugate with the individual having or being at risk for developing Usher syndrome Type IIa.
2. (Previously Presented) The method of claim 1 wherein the biological sample is selected from the group consisting of at least a portion of testis, cochlea, epididymus, ovary, eye, uterus, heart, pancreas, prostate, skin, placenta, spleen, submaxillary gland, small intestine, large intestine, blood vessels, and combinations thereof.

RECEIVED
CENTRAL FAX CENTER

Page 3 of 15

Amendment and Response

Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIA

NOV 09 2004

3. (Original) The method of claim 1 wherein the at least one antibody is detectably labeled.
4. (Original) The method of claim 3 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.
5. (Original) The method of claim 1 wherein the antibody is a monoclonal antibody, a polyclonal antibody, or combinations thereof.
6. (Original) The method of claim 1 wherein the antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.
7. (Original) The method of claim 1 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.
8. (Currently amended) A method for detecting the presence or absence of an usherin protein, the method comprising:
obtaining a biological sample, wherein the biological sample is from a tissue that normally includes the usherin protein in an individual not having Usher syndrome Type IIA;
incubating the biological sample with at least one antibody which is immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 under conditions effective to produce an immunoconjugate if the usherin protein is present, wherein the at least one antibody which is immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 does not cross-react with other non-usherin proteins within the biological sample;
evaluating for the presence or absence of the immunoconjugate;
correlating the presence of the immunoconjugate with the presence of usherin protein, and the absence of the immunoconjugate with the absence of the usherin protein.

RECEIVED
CENTRAL FAX CENTER

Page 4 of 15

Amendment and Response
Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE II A

NOV 09 2004

9. (Original) The method of claim 8 wherein the biological sample is selected from the group consisting of at least a portion of testis, cochlea, epididymus, ovary, eye, uterus, heart, pancreas, prostate, skin, placenta, spleen, submaxillary gland, small intestine, large intestine, blood vessels, and combinations thereof.
10. (Original) The method of claim 8 wherein the antibody is detectably labeled.
11. (Original) The method of claim 10 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.
12. (Original) The method of claim 8 wherein the antibody is a monoclonal antibody, polyclonal antibody, or combinations thereof.
13. (Original) The method of claim 8 wherein the antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.
14. (Original) The method of claim 8 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.
15. (Currently amended) A method of determining whether an individual has or is at risk for developing Usher syndrome Type IIa, the method comprising:
obtaining a biological sample from the individual, wherein the biological sample is from a tissue that normally includes the usherin protein in an individual not having Usher syndrome Type IIa;
incubating the biological sample with a first antibody and a second antibody that are immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 under conditions effective to produce an immunoconjugate if the usherin protein is present,

RECEIVED
CENTRAL FAX CENTER

Page 5 of 15

Amendment and Response

Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIIA

NOV 09 2004

wherein the at least one antibody which is immunoreactive with at least a portion of a human usherin protein having SEQ ID NO:4 does not cross-react with other non-usherin proteins within the biological sample;

evaluating for the presence or absence of the immunoconjugate; and
correlating the presence of the immunoconjugate with the individual not having
Usher syndrome Type IIa, and the absence of the immunoconjugate with the individual having
or being at risk for developing Usher syndrome Type IIa.

16. (Original) The method of claim 15 wherein the immunoconjugate is a sandwich comprising the first antibody, the second antibody, and the human usherin protein.
17. (Original) The method of claim 15 wherein either the first antibody or the second antibody has an attached detectable label.
18. (Original) The method of claim 17 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.
19. (Original) The method of claim 15 wherein at least one of the first or second antibody is a monoclonal antibody.
20. (Original) The method of claim 15 wherein the first antibody is a monoclonal antibody attached to a solid surface and the second antibody is a polyclonal antibody with an attached detectable label.
21. (Original) The method of claim 20 wherein the detectable label is selected from the group consisting of radioactive labels, and non-radioactive labels, and combinations thereof.

RECEIVED
CENTRAL FAX CENTER

Amendment and Response

Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIA

NOV 09 2004

Page 6 of 15

22. (Original) The method of claim 15 wherein the first or second antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.

23. (Original) The method of claim 15 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.

24. (Withdrawn) A test kit for detecting the presence or absence of Usher syndrome Type IIA in an individual comprising:
an antibody that immunoreacts with at least a portion of a human usherin protein, wherein a complement of a polynucleotide encoding the usherin protein is capable of hybridizing to the polynucleotide represented by SEQ ID NO:3 under highly stringent hybridization conditions; and
a detectably-labeled usherin protein.

25. (Withdrawn) The test kit of claim 24 wherein the antibody is a monoclonal antibody, a polyclonal antibody, or combinations thereof.

26. (Withdrawn) The test kit of claim 24 wherein the antibody is attached to a solid surface.

27. (Withdrawn) The test kit of claim 24 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.

28. (Withdrawn) The test kit of claim 24 wherein the antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.

RECEIVED
CENTRAL FAX CENTER

Page 7 of 15

Amendment and Response

Applicant(s): Dominic E. COSGROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIA

29. (Withdrawn) The method of claim 24 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.

30. (Withdrawn) A test kit for detecting the presence or absence of Usher syndrome Type IIA in an individual comprising:
a first antibody that immunoreacts with a portion of a human usherin protein; and
a second antibody that immunoreacts with a portion of a human usherin protein;
wherein a complement of a polynucleotide encoding the usherin protein is capable of hybridizing to the polynucleotide represented by SEQ ID NO:3 under highly stringent hybridization conditions.

31. (Withdrawn) The test kit of claim 30 wherein either the first antibody or the second antibody has an attached detectable label.

32. (Withdrawn) The test kit of claim 31 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.

33. (Withdrawn) The test kit of claim 31 wherein at least one of the first or second antibody is a monoclonal antibody.

34. (Withdrawn) The test kit of claim 31 wherein the first antibody is a monoclonal antibody attached to a solid surface and the second antibody is a polyclonal antibody with an attached detectable label.

35. (Withdrawn) The test kit of claim 34 wherein the detectable label is selected from the group consisting of radioactive labels, non-radioactive labels, and combinations thereof.

RECEIVED
CENTRAL FAX CENTER

Page 8 of 15

Amendment and Response

Applicant(s): Dominic E. COSCROVE
Serial No.: 09/970,318
Filed: 03 October 2001
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER
SYNDROME TYPE IIA

36. (Withdrawn) The test kit of claim 31 wherein the first or second antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.
37. (Withdrawn) The test kit of claim 31 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.
38. (Withdrawn) An antibody that immunoreacts with at least a portion of human usherin protein under conditions effective to produce an immunoconjugate if the usherin protein is present, wherein the absence of an immunoconjugate correlates to the diagnosis of or the individual being at risk for developing Usher Type IIA syndrome, and wherein a complement of a polynucleotide encoding the usherin protein is capable of hybridizing to the polynucleotide represented by SEQ ID NO:3 under highly stringent hybridization conditions.
39. (Withdrawn) The antibody of claim 38 wherein the antibody is a monoclonal antibody, a polyclonal antibody, or combinations thereof.
40. (Withdrawn) The antibody according to claim 38 wherein the antibody is immunoreactive with a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and combinations thereof.
41. (Withdrawn) The antibody according to claim 38 wherein the polynucleotide encoding the usherin protein is represented by SEQ ID NO:3.